The evolution of knowledge on genes associated with human diseases

Thomaz Lüscher-Dias[1], Rodrigo Juliani Siqueira Dalmolin[2,3], Paulo de Paiva Amaral[4], Tiago Lubiana Alves[4], Viviane Schuch[4], Glória Regina Franco[1], Helder I Nakaya[4,5,6*].

[1] Department of Biochemistry and Immunology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil;

[2] Bioinformatics Multidisciplinary Environment—BioME, IMD, Federal University of Rio Grande do Norte, Natal, RN, Brazil;

[3] Department of Biochemistry, CB, Federal University of Rio Grande do Norte, Natal, RN, Brazil;

[4] Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil;

[5] Hospital Israelita Albert Einstein, São Paulo, Brazil.

[6] Scientific Platform Pasteur-University of São Paulo, São Paulo, Brazil

***Correspondence to:** hnakaya@usp.br

Abstract

Thousands of scientific articles describing genes associated with human diseases are published every week. Computational methods such as text mining and machine learning algorithms are now able to automatically detect these associations. In this study, we used a cognitive computing text-mining application to construct a knowledge network comprised of 3,723 genes and 99 diseases. We then tracked the yearly changes on these networks to analyze how our knowledge has evolved in the past 30 years. Our approach helped to unravel the molecular bases of diseases over time, and to detect shared mechanisms between clinically distinct diseases. It also revealed that multi-purpose therapeutic drugs target genes which are commonly associated with several psychiatric, inflammatory, or infectious disorders. By navigating in this knowledge tsunami, we were able to extract relevant biological information and insights about human diseases.

Keywords: meta-research, evolution of knowledge, genes, human diseases, network analysis

Introduction

Thousands of scientific articles are published every day, piling up with millions of already published papers (Fortunato et al., 2018). Keeping abreast of scientific significance has become an overwhelming task for researchers in their own fields and in other areas of science. In this scenario, computational methods such as text mining, machine learning, and cognitive computing are helping scientists to summarize published scientific literature. Recently, machine learning approaches have been used to analyze and integrate a variety of biological and medical data (Littmann et al., 2020; Zitnik et al., 2019). These include methods that integrate electronic health records (Rajkomar et al., 2018), capture latent knowledge from the material science literature (Tshitoyan et al., 2019), and discover potential novel drugs to treat psychiatric and neurological disorders using cognitive computing and network medicine analysis of the medical literature (Lüscher Dias et al., 2020).

Particularly, the field of molecular biology has seen a remarkable increase in the number of new studies in recent decades. This has resulted in a large number of genes associated with diseases. As a positive consequence of this efflux of genetic knowledge, diseases that were previously not known to have common etiologies are now being connected through their shared alterations in gene expression and interaction patterns, which has opened many potential new roads for clinical advances (Brooks et al., 2014; Carson et al., 2017; Lees et al., 2011; Postma et al., 2011). One significant example of this trend is the association between psychiatric disorders and immune-related diseases (Gibney and Drexhage, 2013; Marrie et al., 2017; Wang et al., 2015).

Network medicine (Barabási et al., 2011), a contemporary approach to studying relationships between genes and diseases, has also been made possible because of the large

amounts of data on genes and diseases available online. Moreover, knowledge networks, that is, complex graphs that connect concepts according to the established knowledge, can be analyzed under the network medicine framework to produce novel insights from medical knowledge (Bai et al., 2016; Lüscher Dias et al., 2020).

In this study, we used IBM Watson for Drug Discovery (WDD; Y. Chen et al., 2016), a cognitive computing text-mining application, to extract known relationships between genes and psychiatric, inflammatory, and infectious diseases from the peer-reviewed literature published between 1990 and 2018. We developed knowledge networks of genes and diseases and monitored the evolution of these relationships yearly. We then quantified and described how genes were connected to each category of disease over this period and how key biological functions unraveled as new genes were added to the network. We also found pairs of diseases from different categories that significantly share genes with each other, indicating underlying clinical proximity between diseases that have not been historically related. Lastly, we explored the genes that were common to all psychiatric, inflammatory, or infectious diseases and investigated which drugs target them. By using a network medicine approach, we were able to extract relevant biological information and new insights of genes, pathways, and therapeutic drugs associated with complex human disorders.

Results

Evolution of knowledge on the molecular bases of human diseases.

We used WDD, a cognitive computing text-mining application, to identify connections between genes and diseases in millions of peer-reviewed studies (Y. Chen et al., 2016). For each year from 1990 to 2018, we queried WDD to obtain gene sets related to 99 inflammatory, psychiatric, and infectious diseases (Table S1). WDD detects terms of interest, such as genes and diseases, in scientific texts (e.g., PubMed abstracts and full text journal articles) and finds contextual elements connecting them (e.g., prepositions and verbs). These connections can be extracted from many distinct sources of evidence such as gene expression alterations, genome-wide association studies, or protein expression experiments. A confidence score is established for each relationship based on the strength of the detected semantic association and also the number of documents in which the connection is found. However, the type of study from which the association is obtained is not considered for the calculation of the evidence score. Here, we kept only gene-disease relationships with a confidence score equal or higher than 50%, and which were supported by at least 2 studies.

Next, we built yearly disease-disease networks connecting inflammatory, infectious, and psychiatric diseases according to the significance of the genes shared by each pair of diseases (Fig. 1A). These networks were cumulative: the 2018 network (Fig. 1A, rightmost network) displays all connections found in the entire period, while the 2000 network (Fig. 1A, second network from left to right), for instance, contains all connections from 1990 up to that year. The 1990 network (Fig. 1A, leftmost network) depicts the relationships between diseases from the beginning of the literature registries up to 1990.



Figure 1. Evolution of knowledge on the molecular bases of human diseases. A. Disease-disease knowledge network on infectious, inflammatory, and psychiatric disorders from 1990 to 2018. Nodes represent diseases and are proportional to the number of genes associated with each disease in each year. Edge weights are proportional to the significance of gene-sharing between each pair of diseases. Only edges with a p-value < 0.01 are depicted. **B.** Cumulative number of genes associated with each disease category and with all diseases from 1990 to 2018. **C.** Distribution of the number of genes associated with each disease and category in 2018. **D.** Number of new genes added to the network in each category per year. **E.** Number of new genes added to the network in selected diseases each year. **Color code:** Green – infectious diseases, orange – inflammatory diseases, and blue – psychiatric disorders.

We then assessed how these relationships evolved over the past three decades (1990–2018) and explored the historical trends of the new genes connected to the network during the period (Fig. 1B–E and Table S2). In 1990, only 95 genes were connected in the network (Fig. 1B), and no association between psychiatric disorders and inflammatory or infectious diseases could be established through shared genes (Fig. 1A). Accordingly, the overall similarity between diseases (between or within categories) was low in 1990 (Fig. S1). From 1990 to 2010, with the constant increase in the number of genes associated with diseases in all categories, a preliminary approximation between inflammatory and infectious diseases was observed (Fig. 1A, second panel, and Fig. S1A). During the next 9 years (2010 to 2018), the new genes added to the network (Fig. 1B) resulted in a strengthening of the connections between infectious and inflammatory diseases, and a fast approximation between psychiatric disorders and the other two categories (Fig. 1A, fourth panel, and Fig. S1A). Meanwhile, the proximity of diseases within

118 the same categories also increased (Fig. S1B). Inflammatory diseases occupy a central position
119 in the 2018 network (Fig. 1A, fourth panel), which reflects their high between- and within-
120 category similarities sustained throughout the 30-year period (Fig. S1). Psychiatric and
121 infectious diseases presented the lowest similarity between each other (Figs. 1A and S1).



122

123

124 **Figure S1. Evolution of knowledge – supplementary results. A and B.** Evolution of the
125 mean disease-disease similarity between diseases of different categories (**A**) or within diseases
126 of the same categories (**B**). **C.** Comparison of the total number of papers retrieved from PubMed
127 on diseases of all categories that were connected to less than 100 genes in the 2018 network
128 with that connected to more than 100 genes in 2018. The *p*-value is obtained from the t-test of
129 the mean comparison between the two distributions.

130

131 In 2018, a total of 3,723 genes were present in the network (Fig. 1B). The number of
132 genes associated with each disease in the three different categories in 2018 also varied (Fig.
133 1C). The infectious diseases with the highest number of connected genes in 2018 were hepatitis
134 B (414 genes), hepatitis C (506 genes), and HIV infection (856 genes; Fig. 1C). However, 55 of

63 infectious diseases were connected to less than 100 genes in 2018 (Fig. 1C). The most connected inflammatory diseases were psoriasis (346 genes), systemic lupus erythematosus (393 genes), and arthritis (490 genes; Fig. 1C). In the category of psychiatric disorders, Alzheimer's disease was the most connected (657 genes), followed by schizophrenia (547 genes) and depression (402 genes; Fig. 1B). The imbalance in the distribution of genes connected to infectious diseases likely reflects a bias in the research interest toward the discovery of genes related to diseases already connected to more genes. In fact, the 2018 network showed that the number of scientific papers that mentioned poorly connected diseases (less than 100 genes) is significantly lower than the number of papers published on highly connected diseases (more than 100 genes) (Fig. S1C).

Distinct historical trends of discovery were seen for each disease category (Fig. 1D and Table S3). Prominent peaks of gene-association discovery occurred in 1996 for infectious diseases, in 2005 for inflammatory diseases, and in 2013 for psychiatric disorders (Fig. 1C). From 2010 to 2017, the rate of gene discovery in all three categories increased (Fig. 1C). The significant increase in the number of genes associated with infectious diseases observed in 1996 was mostly driven by 154 new genes associated with HIV infection (Fig. 1D), which corresponded to 50% of the new genes added to the network in that year (Table S3). The triple therapy for HIV using nucleoside reverse-transcriptase inhibitors and protease inhibitors was established in 1996 (Hammer et al., 1996), which likely influenced this outburst of genetic discovery. The 2005 increase in the number of genes associated with inflammatory diseases was mostly related to the new genes connected to psoriasis (41 genes) and systemic lupus erythematosus (33 genes; Fig. 1D), which together corresponded to 20% of the new genes associated with all of the diseases in 2005 (Table S3). The Th_{17} cell lineage was discovered in

2005 (Langrish et al., 2005), a cell type that has since been strongly associated with autoimmune and infectious diseases (Zambrano-Zaragoza et al., 2014). In 2013, a large number of new genes were associated with Parkinson's disease (165 genes Fig. 1D), which corresponded to 17% of the new genes in the network in that year (Table S3). We could not detect any specific scientific landmark in 2013 that could explain this peak. Nevertheless, important genes related to the innate immune response to pathogens and inflammation are among the new genes associated with Parkinson's disease in 2013, such as interleukin 1 beta (IL1B) and the p105 subunit of the nuclear factor kappa B (NFKB1).

Evolution of disease relationships between categories

Next, we investigated the evolution of the similarity between diseases from different categories according to their shared genes (see Methods section). For the top 9 most connected diseases of each category in 2018 (i.e., diseases connected to more genes), we detected the diseases from the other two categories with the most significant gene sharing between them and analyzed how these relationships evolved from 1990 to 2018 (Figs. 2, S2, S3, and S4). Alzheimer's disease was the psychiatric disorder with the highest similarity to inflammatory diseases in 2018, including arthritis and systemic lupus erythematosus (Fig. 2A). The relationships between Alzheimer's disease and these disorders grew steadily in significance from 1990 to 2018 (Fig. S2A), which captures the now well-established relevance of inflammatory processes in the pathophysiology of Alzheimer's disease (Newcombe et al., 2018). Surprisingly, fibromyalgia was similar to several psychiatric diseases: depression, anxiety, bipolar disorder, schizophrenia, and Huntington's disease (Figs. 2A and S2). The total number of genes associated with fibromyalgia in 2018 was low (25 genes), but 72% of these (17 genes)

are also associated with depression. These are genes related to nervous system development, such as brain derived neurotrophic factor (BDNF), nerve growth factor (NGF), and neuropeptide Y (NPY), and inflammatory response, including interleukin 6 (IL6), C-X-C motif chemokine ligand 8 (CXCL8), and tumor necrosis factor (TNF). In fact, fibromyalgia patients often present psychiatric comorbidities such as depression and anxiety (Galvez-Sánchez et al., 2020).



Figure 2. Evolution of disease relationships between categories. A. Disease-disease similarity between diseases of different categories in the 2018 network according to their shared genes. The similarity score was defined as the $-\log_{10}$pval of the Fisher's exact test result of the gene overlap between each disease pair. Each heatmap represents the similarity score between diseases of two different categories: **A.** psychiatric versus inflammatory diseases. **B.** psychiatric versus infectious diseases. **C.** inflammatory versus infectious diseases.

Among infectious diseases, herpes was the most similar disease to autism, schizophrenia, and Huntington's disease and was also among the top 5 most similar infectious diseases to depression, Parkinson's disease, and Alzheimer's disease (Figs. 2B and S3). Herpes infection might be associated with the development of Alzheimer's disease (Harris and Harris, 2015); the typical amyloid-β deposition that occurs in the brain of Alzheimer's disease patients could be an innate immunity mechanism to fight herpes virus infections (Eimer et al., 2018). Our results indicate that there has been latent evidence of that association since the early 2000s in the scientific literature (Fig. S3A). In the 2005 network, Alzheimer's disease and herpes virus infection shared 14 genes, which represented 58% of the known genes associated with herpes infection at that time.



205

206

207 **Figure S2. Disease-disease similarity evolution between psychiatric and inflammatory**
208 **diseases from 1990 to 2018. A–I.** Evolution of the similarity between psychiatric disorders and
209 inflammatory diseases: Alzheimer's disease (**A**), anxiety disorder (**B**), autism (**C**), bipolar
210 disorder (**D**), dementia (**E**), depression (**F**), Huntington's disease (**G**), Parkinson's disease (**H**),
211 and schizophrenia (**I**). Similarity scores represent the $-\log_{10}$pval of the Fisher's exact test result
212 of the gene overlap between each disease pair in each year from 1990 to 2018.



Figure S3. Disease-disease similarity evolution between psychiatric and infectious diseases from 1990 to 2018. A–I. Evolution of the similarity between psychiatric disorders and infectious diseases: Alzheimer's disease (**A**), anxiety disorder (**B**), autism (**C**), bipolar disorder (**D**), dementia (**E**), depression (**F**), Huntington's disease (**G**), Parkinson's disease (**H**), and schizophrenia (**I**). Similarity scores represent the $-\log_{10}$pval of the Fisher's exact test result of the gene overlap between each disease pair in each year from 1990 to 2018.

Autoimmune inflammatory diseases, such as systemic lupus erythematosus, arthritis, and psoriasis, also showed strong gene sharing with viral infections such as hepatitis B and C, respiratory syncytial virus (RSV) infection, influenza, and HIV (Figs. 2C and S4). The association between viral infections and autoimmune diseases is well documented (Getts et al., 2013). For instance, the SARS-CoV-2 virus can trigger Guillain–Barré syndrome, a neurological autoimmune disease, in COVID-19 patients (Dalakas, 2020). Dengue patients also present a higher risk of developing autoimmune diseases, such as systemic lupus erythematosus and vasculitis (Li et al., 2018), an association that was also captured in our analysis of the scientific literature since the late 1990s (Fig. S4I).



232

233

234 **Figure S4. Disease-disease similarity evolution between inflammatory and infectious**
235 **diseases from 1990 to 2018. A–I.** Evolution of the similarity between psychiatric disorders and
236 infectious diseases: age related osteoporosis (**A**), ankylosing spondylarthritides (**B**), arthritis (**C**),
237 chronic ulcerative colitis (**D**), Crohn's disease (**E**), psoriasis (**F**), sarcoidosis (**G**), scleroderma
238 (**H**), and systemic lupus erythematosus (**I**). Similarity scores represent the $-\log_{10}$pval of the
239 Fisher's exact test result of the gene overlap between each disease pair in each year from 1990
240 to 2018.

We then examined the number of publications retrieved from PubMed using the topmost similar pairs of diseases from distinct categories as queries (see Methods section; Fig. 3). The goal was to find out whether the gene-sharing similarities between diseases from different categories detected in our networks could also be captured from direct co-occurrence in the general peer-reviewed literature over the 30-year period. For each disease pair, we obtained a ratio between the similarity score of the diseases (i.e., the significance of the gene sharing between them) and the total number of studies retrieved from PubMed that mention both diseases of the pairs together (Table S4). This similarity-to-paper ratio was used to detect potentially understudied pairs of diseases that significantly share genes. Low similarity-to-paper ratio values (Figs. 3A and 3B, light green, and Table S4) represent similar diseases with many papers already published about them or dissimilar disease pairs. An example of such a pair is fibromyalgia and depression. These diseases have significant gene sharing and also hundreds of scientific papers that explore their relationship in the literature (Fig. 3B). Conversely, the genetic association between osteoporosis and mycobacterial infection is low and so is the number of papers that investigate these diseases together (Fig. 3B). These cases were considered as examples of a low knowledge gap between the genetic similarity obtained from our network analysis and the established literature coverage of the disease pairs.



Figure 3. Evolution of the knowledge gap between diseases of different categories. A. Number of disease pairs according to the similarity-to-paper ratio index. This index was obtained as a ratio of the similarity score to the total number of papers published for each disease pair in 2018. Low similarity-to-paper ratio (<10) is colored in blue; intermediate similarity-to-paper ratio (10 < ratio < 40) is colored in yellow; and high similarity-to-paper ratio (>40) is colored in pink. **B.** Selected cases of disease pairs with low, intermediate, or high similarity-to-paper ratios depicting the evolution in the number of papers on each pair and the evolution of the similarity between them.

Cases with an intermediate similarity-to-paper ratio (Figs. 3A and 3B, yellow, and Table S4) were considered as cases of moderate knowledge gap (Fig. 3A), which was the case for arthritis and hepatitis B (Fig. 3B). As previously mentioned, several recent studies have explored the association between viral infections and autoimmune diseases (Dalakas, 2020; Getts et al., 2013; Li et al., 2018). In 2018, there were over 250 published papers in which arthritis and hepatitis B were mentioned together (Fig. 3B). Virally mediated arthritis represents ~1% of all arthritis cases, including cases related to hepatitis B infection (Marks and Marks, 2016). Scientists have detected the hepatitis B virus in the synovial fluid of rheumatological patients, which could contribute to the pathogenesis of arthritis (Chen et al., 2018). Although these diseases are known to be clinically associated at least since the 1970s (Mirise and Kitridou, 1979), our results show that the knowledge on the gene sharing between them increased rapidly after 2015, which was not followed at the same rate by the number of papers published on the two diseases together. This represents a potential gap to be explored by novel research on the genetic bases of the relationship between arthritis and hepatitis B.

Lastly, we considered the disease pairs with strong gene sharing and few studies supporting a direct association as cases of a high knowledge gap (Figs. 3A and 3B, pink, and Table S4). We suggest that these cases might represent potentially underexplored fields of research that deserve further investigation. Surprisingly, the number of papers published until 2018 that mentioned psoriasis and malaria together was neglectable (Fig. 3B). These diseases share 31 genes, one-third of the genes associated with psoriasis, and over 10% of the genes associated with malaria in the 2018 network. Hydroxychloroquine, a drug used to treat malaria (Ben-Zvi et al., 2012) and rheumatic diseases, such as arthritis and lupus (Ben-Zvi et al., 2012),

292 can trigger psoriatic lesions (Balak and Hajdarbegovic, 2017). Among a few papers in which
293 malaria and psoriasis are mentioned together, there is a report from 2014 that describes cases
294 of hydroxychloroquine-induced psoriasis in patients undergoing malaria treatment (Gravani et
295 al., 2014). The authors of this study suggest that there should be guidelines for the
296 management of psoriasis patients who are also at risk of malaria (Gravani et al., 2014). Our
297 findings corroborate the need for future studies to investigate the association between these
298 diseases.
299
300 **Evolution of biological pathways**
301 We performed a gene overrepresentation analysis (ORA) against Reactome pathways
302 with the genes associated with the top 9 most connected diseases in each year from 1990 to
303 2018 (Figs. 4-6 and Table S5). We detected 433 Reactome pathways that presented significant
304 enrichment (p.adjust < 0.01) among the genes of at least one disease (Table S5). Functional
305 enrichment analysis, such as ORA, often yields too many significant pathways, making these
306 results difficult to interpret at the individual pathway level. For this reason, we used a network
307 approach to reduce the complexity of the obtained set of enriched pathways (see Methods
308 section). Briefly, we built a pathway network (Fig. 4) with the significant Reactome pathways
309 obtained from the ORA. We connected these pathways to each other according to the gene
310 sharing between them, similar to what was done in Fig. 1A. We then identified 11 clusters of
311 closely connected pathways in the network and annotated these clusters according to the main
312 biological functions of the pathways within them (Fig. 4 and Table S5). One of the detected
313 clusters grouped several pathways associated with interferon-stimulated genes, interleukins,
314 and antigen presentation (Fig. 4 and Table S5). The pathways in this cluster were significantly

315 enriched among the genes of diseases in all categories, including malaria, HIV infection,
316 arthritis, lupus, depression, and Alzheimer's disease (Fig. 5). The pathways related to
317 interleukin signaling (e.g., "interleukin 10 signaling"), for instance, were among the top enriched
318 pathways associated with depression genes in the 2018 network (Fig. 5 and Table S5). Another
319 cluster of pathways that showed consistent enrichment across all disease categories was NFκB-
320 mediated inflammation induced by toll-like receptors (TLRs), T-cell receptors (TCRs), and B-cell
321 receptors (BCRs; Fig. 4). These results illustrate the most recurring theme detected in our
322 study: psychiatric, inflammatory, and infectious diseases share common immunological
323 mechanisms that are mostly related to innate immunity and inflammation.



Figure 4. Reactome term network built from the ORA results of the genes associated with human diseases in 2018. Significant Reactome ORA terms (p.adjust < 0.01) obtained from the genes of the top 9 diseases in the 2018 network were connected to each other according to the significance of the gene sharing between them (edge weight). Only terms with a gene sharing with a p.adjust < 0.01 were connected. We detected 11 clusters (node colors) of closely related terms using the Louvain clustering algorithm in the R package *igraph* (Csardi and Nepusz, 2006) and compared the enrichment score distribution of the terms in these clusters in each disease category (box plots). Box plots are colored according to the disease categories: green – infectious diseases, orange – inflammatory diseases, and light blue – psychiatric disorders. Dots

334 in the box plots represent individual enriched Reactome pathways that belong to each network
335 cluster.
336



337
338

339 **Figure 5. Key biological pathways are enriched among the genes associated with human**
340 **diseases in 2018. A.** ORA networks depicting the enrichment score of Reactome pathways in
341 selected infectious, inflammatory and psychiatric disorders. The networks in A have the same
342 topology of the network in Figure 04. The nodes are colored according to the logarithm of
343 enrichment score ($-\log_{10}$pval) of the terms represented by each node. **B.** ORA enrichment score
344 distribution of the terms in the clusters and diseases from panel A. Box plots are colored
345 according to the category of each disease: green – infectious, orange – inflammatory, and light

346 blue – psychiatric. Dots in the box plots represent individual Reactome pathways that belong to
347 the clusters listed in the y axis and that were enriched in each disease.
348
349 Conversely, we found a cluster of closely connected pathways related to
350 neurotransmission that were enriched mostly among the genes of psychiatric disorders (Fig. 4
351 and Table S5). However, three inflammatory and infectious diseases (hepatitis B, arthritis, and
352 HIV infection) presented enrichment for pathways in this cluster (Fig. 5 and Fig. S5). The genes
353 related to these diseases presented enrichment for the pathway “transcriptional regulation
354 MECP2”, a member of the neurotransmission cluster. Methyl CpG binding protein 2 (MECP2) is
355 located in the X chromosome, and mutations in this gene are the primary cause of Rett
356 syndrome (Liyanage and Rastegar, 2014). There is no evidence in the scientific literature that
357 there is a link between HIV infection or hepatitis B and Rett syndrome, but recent studies
358 indicate a link between this neurodevelopmental disorder and autoimmune diseases, including
359 arthritis (De Felice et al., 2016). Moreover, AIDS patients can develop neurological
360 manifestations similar to those observed in Rett patients, such as cognitive dysfunction and
361 movement disorders (Brew and Garber, 2018). Our results suggest that the similarity between
362 Rett syndrome and autoimmune diseases might also occur for infectious diseases of viral
363 etiology.

364



365 **Figure S5. ORA network analysis of genes associated with inflammatory, infectious, and**
366 **psychiatric diseases.** Enrichment score distribution of the terms in the clusters from Fig. 4 for
367 diseases not depicted in Fig. 5. Box plots illustrate the distribution of the enrichment scores of
368 the Reactome pathways in each cluster.

369

370 We also detected other clusters of pathways with similar enrichment results between
371 diseases of different categories (Fig. 4). The genes related to arthritis and those related to
372 Alzheimer's disease presented enrichment for pathways related to the extracellular matrix
373 organization, coagulation, and lipoprotein metabolism (Fig. 5). In arthritis, fibroblast-like
374 synoviocytes become hyper-inflammatory and disrupt the extracellular matrix integrity, which
375 leads to the degradation of synovial joint collagen (Nygaard and Firestein, 2020). In Alzheimer's

disease, some extracellular matrix macromolecules seem to promote the production and stabilization of amyloid β, while others act to protect neurons from amyloidosis (Sethi and Zaia, 2017). The pathways in the signal transduction on growth factor stimulation and GPCR-mediated signaling clusters were also enriched among the genes of diseases in all categories (Figs. 4, 5, and S5). This result was expected because the genes involved in signal transduction and intracellular signaling are usually shared between cellular pathways and are involved in virtually all biological functions relevant to diseases (Figs. 5 and S5).

After determining the major biological functions related to the genes connected to infectious, inflammatory, and psychiatric diseases in the 2018 network, we investigated how this knowledge evolved from 1990 to 2018 (Fig. 6). The pathways related to interferon-stimulated genes, interleukins, and antigen presentation became enriched for the genes associated with inflammatory and infectious diseases already since the early 1990s (Fig. 6). Surprisingly, this enrichment appeared earlier for inflammatory diseases, despite the highly relevant role of interferon-stimulated genes and antigen presentation in infectious diseases. Conversely, there was a significant increase in the enrichment of these pathways for the genes related to depression, autism, and schizophrenia since 2010 (Fig. 6). Recently, the specific roles of the immune system in psychiatric diseases begun to be revealed (Chen et al., 2016; de Baumont et al., 2015; Dong et al., 2018; Madore et al., 2016; Yuan et al., 2019). Particularly, neuroglial cells have gained importance as key neuroimmune players in the development of autism (microglia and oligodendrocytes; Scuderi and Verkhratsky, 2020), Alzheimer's disease (microglia; Clayton et al., 2017), and schizophrenia (astrocytes; Gandal et al., 2018). The association of pathways related to apoptosis, senescence, and cell differentiation with psychiatric disorders has also occurred recently, except with Alzheimer's disease, which began early in the period (Fig. 6).

399 Alzheimer's, Parkinson's, and Huntington's diseases are neurodegenerative conditions in which
400 chronic neuronal death happens in distinct parts of the brain (Dugger and Dickson, 2017). We
401 also found an increasing association in recent years of genes related to autism and depression
402 to cell fate pathways (Fig. 6), showing that these disorders might also have a neurodegenerative
403 component. In fact, apoptosis and cell death in response to stress and inflammation are relevant
404 factors in the pathogenesis of autism (D. Dong et al., 2018) and depression (Leonard, 2018).



405 **Figure 6. Evolution of knowledge on biological pathways.** Ridge plots of the enrichment
406 score of selected clusters from the network in Figure 04 for the top 9 diseases in each category
407 from 1990 to 2018. The height of the ridges are proportional to the mean enrichment score
408 (mean $\log_{10}$pval) of the Reactome pathways in each cluster listed in the y axis.

409

410 **Evolution of drug target hub genes**

411 Lastly, we examined how drugs that are used to treat inflammatory, infectious, and
412 psychiatric diseases target the genes that are shared between the three categories. We found
413 that 345 genes were common to all disease categories (Fig. 7A). Ninety-nine genes were
414 shared only between inflammatory and psychiatric diseases; 259 were common only between
415 psychiatric and infectious diseases; and a total of 409 genes were related exclusively to
416 inflammatory and infectious diseases (Fig. 7A). The remaining genes were unique to
417 inflammatory (493 genes), psychiatric (869 genes), and infectious diseases (1,209 genes; Fig.
418 7A).



Figure 7. Evolution of drug target hub genes. A. UpSet plot showing the common genes between all categories (hub genes), between two categories exclusively and genes that are unique to each category. **B.** Number of therapeutic drugs of inflammatory, infectious, and psychiatric diseases that target the top 20 target hub genes according to the comparative toxicogenomics database (CTD). **C.** Timeline of the association of the top 20 target hub genes to the gene-disease network. The year in which each gene was associated with the first disease of each category is depicted by the circles with distinct colors for each category. **D.** Number of hub genes targeted by the top 20 drugs that target more hubs according to CTD. **E.** Drug-gene network depicting the top 20 drugs and that target hub genes. We selected a few drugs and illustrated their molecular structure and diseases for which they are listed as therapeutic according to CTD.

We used the comparative toxicogenomics database (CTD; Davis et al., 2021) to find drugs that have a therapeutic relationship with the top 9 diseases and the list of genes that these drugs affect (see Methods section). From these lists, we highlight the top 20 most common target genes of the therapeutic drugs listed by CTD (Fig. 7B). Among these genes, IL6, TNF, and interferon gamma (IFNG) were already connected to inflammatory diseases in the 1990 network and were gradually related to diseases in the other two categories until 2002 (Fig. 7C). Interleukin 1 beta (IL1B), B-cell lymphoma 2 (BCL2), tumor protein P53 (TP53), and CXCL8 also appeared in our networks in the early 1990s and were first connected to inflammatory diseases (Fig. 7C). Eight drug target genes were first connected to psychiatric disorders (Fig. 7C): caspase 3 (CASP3; 1996), prostaglandin-endoperoxide synthase 2 (PTGS2; 1997), heme oxygenase 1 (HMOX1; 2000), BCL-2-associated X (BAX) and mitogen-

443 activated protein kinase 1 (MAPK1; 2001), RAC-alpha serine/threonine-protein kinase (AKT1;
444 2003), nuclear factor erythroid 2-related factor 2 (NFE2L2; 2007), and mitogen-activated protein
445 kinase 1 (MAPK3; 2008). The other 5 genes were first connected to infectious diseases (Fig.
446 7C): NFkB P65 Subunit (RELA; 1996), poly(ADP-Ribose) polymerase 1 (PARP1) and ATP
447 binding cassette subfamily B member 1 (ABCB1; 1999), cyclin dependent kinase inhibitor 1A
448 (CDKN1A; 2001), and caspase 8 (CASP8 ; 2010). All top 20 drug target genes were first
449 connected to one of the categories until 2010, with the majority of new connections happening
450 in the 1990s (Fig. 7C). These are very well-known genes involved in inflammation (e.g., IL6 and
451 IL1B), innate immunity (e.g., IFNG), apoptosis (e.g., CASP3 and CASP8), cell cycle (e.g.,
452 TP53), and other key biological functions that are altered in several diseases.

453 Next, we found the top 20 therapeutic drugs that affect the most hub genes of
454 inflammatory, psychiatric, and infectious diseases (Fig. 7D). Valproic acid, a class I histone
455 deacetylase (HDAC) inhibitor (Göttlicher et al., 2001), was the drug that affected the most hub
456 genes, 259 (Fig. 7D). According to CTD, among the diseases we analyzed in this study, valproic
457 acid is a therapeutic drug for anxiety, autism, bipolar disorder, and schizophrenia (Fig. 7E). This
458 drug is also an efficient anti-convulsant used to treat epilepsy (Tomson et al., 2016) because it
459 facilitates gamma-aminobutyric acid (GABAergic) neurotransmission (Chateauvieux et al.,
460 2010). There is extensive evidence in the literature of the anti-inflammatory effects of valproic
461 acid and its potential use to treat conditions such as spinal cord injury (S. Chen et al., 2018),
462 renal ischemia (Costalonga et al., 2016), and sepsis-induced heart failure (Shi et al., 2019).
463 Valproate was also speculated as a potential repurposing candidate to treat diseases caused by
464 infectious agents, such as COVID-19 (Pitt et al., 2021) and toxoplasmosis (Goodwin et al.,
465 2008). HDAC inhibitors promote epigenetic modifications in the genome that induce the

466 expression of genes in many biological functions and cell types (Hull et al., 2016). This could
467 explain valproic acid's versatility and why it ranked first in our analysis.

468 Among the other top 20 drugs, we found molecules that are currently under investigation
469 for repositioning from one disease category to another. Methotrexate (Fig. 7D), which affects
470 141 genes among the 345 hubs, is used to treat several inflammatory diseases, including
471 psoriasis, lupus, and arthritis (Fig. 7E). Recently, a randomized clinical trial revealed a potential
472 for methotrexate to treat positive symptoms in schizophrenia patients (Chaudhry et al., 2020).
473 The authors of the trial argue that this effect of methotrexate might be achieved through
474 resetting of systemic regulatory T-cell control of immune signaling, which is also the way this
475 drug is thought to act in autoimmune diseases (Chaudhry et al., 2020). The use of anti-
476 inflammatory drugs for the treatment of neuropsychiatric diseases gained traction in recent
477 years (Kohler et al., 2016; Ozben and Ozben, 2019; Pandurangi and Buckley, 2020; Rosenblat
478 et al., 2016) influenced by the increasing evidence that these disorders have underlying immune
479 causes, which we have extensively demonstrated in this study. Dexamethasone (Fig. 7D) is a
480 glucocorticoid anti-inflammatory drug listed in CTD as a therapy for arthritis and depression (Fig.
481 7E), but it is also used to treat several other inflammatory disorders. Indeed, dexamethasone
482 was one of the few drugs submitted to randomized clinical trials that reduced mortality in
483 COVID-19 patients subjected to invasive ventilation (RECOVERY Collaborative Group, 2021).
484 Several of the other top 20 drugs were also listed in CTD to be used as therapy for diseases of
485 different categories, such as cyclosporine (hepatitis C and psoriasis), indomethacin (Alzheimer's
486 and autoimmune diseases), dronabinol (neuropsychiatric diseases and HIV infection), and
487 quercetin (anxiety and influenza; Fig. 7E).
488

Discussion

Similar to the exponential increase in the number of published papers seen in the past decades (Fortunato et al., 2018), the number of genes associated with psychiatric, inflammatory, and infectious diseases have also increased significantly in the past 30 years . This rapid growth in knowledge about the genetic underpinnings of these diseases can be directly attributed to at least two historical landmarks: the publication of the human genome in 2001 (Lander et al., 2001; Venter et al., 2001) and the advent of high-throughput DNA-sequencing technologies (Margulies et al., 2005). Discrete advances in genes associated with specific diseases could also be spotted throughout the period analyzed here. In 1996, the triple therapy for HIV was developed using nucleoside reverse-transcriptase inhibitors and protease inhibitors (Hammer et al., 1996). In the same year, 50% of the new genes added to the knowledge network were connected to HIV infection. In 2005, a peak of novel genes associated with psoriasis and systemic lupus erythematosus was detected. This year also saw the discovery of the Th_{17} cell lineage (Langrish et al., 2005). The central role of these pro-inflammatory cells in the pathogenesis of autoimmune and infectious diseases was later identified (Zambrano-Zaragoza et al., 2014). Indeed, the key genes of the differentiation and maintenance of the Th_{17} phenotype in $CD4^+$ T lymphocytes, such as interleukin 17F (IL17F), interleukin 21 (IL21), the peroxisome proliferator-activated receptor gamma (PPARG), and the fatty acid-binding protein 5 (FABP5), were connected to psoriasis and systemic lupus erythematosus in the network in 2005 (Hwang, 2010; Nalbant and Eskier, 2016).

One of the advantages of using text mining and network medicine to study the relationships between genes and diseases is the possibility of detecting novel connections from established scientific knowledge. When two diseases share a genetic mechanism, they can also

present common clinical or epidemiological characteristics, despite having distinct etiological backgrounds (Barabási et al., 2011). These similarities can inform researchers of potential treatment options (Lüscher Dias et al., 2020). Here, we showed that diseases from inflammatory, psychiatric, and infectious etiologies significantly share genes with each other. This sharing was strong between disease pairs that were well studied together, such as depression and fibromyalgia. Conversely, the gene sharing between psoriasis and malaria could be perceived in our knowledge networks since the 2000s, but the number of papers featuring the two conditions together in PubMed is virtually null. We detected a few such cases, mostly involving neglected infectious diseases, which could explain the knowledge gap. We also found cases of diseases that just recently began to share genes that also lack many publications directly connecting them in the literature. A case in point is autism and RSV. We also found disease pairs, such as dementia and *Toxoplasma gondii* infection, for which there have been direct associations in the literature since 1990, but that just recently started to share genes in the network. Our results reveal potentially underexplored pathways for future research on the association between diseases of distinct categories and also for the discovery of new genes related to well-studied disease pairs.

The sharing of genes between diseases from distinct categories also reflects in the overlap of biological functions, particularly those related to immunological processes. The genes of several diseases in all categories presented enrichment for Reactome pathways related to the interferon response, cytokines, and NFkB-mediated inflammation. This pattern was detectable in our networks since the early 1990s for inflammatory diseases and gradually appeared for infectious and psychiatric diseases as well. Pathways associated with neurotransmission were almost exclusively enriched among the genes of psychiatric diseases.

Nevertheless, we found enrichment for a neurotransmission-related pathway, “transcriptional regulation by MECP2”, among the genes of HIV infection and hepatitis B that could point to a connection between these disorders and Rett syndrome, a neurological condition. Our functional enrichment results also highlighted the relevance of core cellular functions in diseases of all categories, such as signal transduction and the regulation of gene expression by transcription factors.

Our network medicine text mining approach also revealed how shared genes between disease categories can signal toward common therapeutic solutions. The findings presented in the last section of our study emphasize the relevance of drugs that target shared genes for the treatment of distinct diseases. Our results show that the genes targeted by therapeutic drugs shared by inflammatory, psychiatric, and infectious diseases have been associated with these disorders early in the past 30 years of scientific research. These genes are associated with inflammation, the cell cycle, apoptosis, and central pathways of cellular function. We also demonstrated that well-established and promising cases of repositioning involve drugs that target shared genes between diseases. Future studies should aim to reveal more common molecular mechanisms between these categories of diseases as well as to harness that knowledge for novel drug discovery and repurposing.

In summary, we could apply a machine learning and cognitive computing text-mining strategy using WDD to extract knowledge about genes related to inflammatory, infectious, and psychiatric diseases from the scientific literature and depict how this knowledge evolved during the past 30 years.

Methods

Knowledge network construction

We built knowledge networks containing interactions between diseases and genes using the WDD (Y. Chen et al., 2016). WDD discovers connections between genes and diseases using a natural language processing algorithm that reads full texts from PMC open access journals, patents, and abstracts in the MEDLINE (PubMed) database. A connection is found when two terms of interest (e.g., genes and diseases) are detected in the same sentence, separated by a preposition or a verb. These connections can be derived from many sources of evidence, such as gene expression, disease-associated mutations, genome-wide association studies, or protein expression experiments. WDD attributes a confidence score (0–100%) to each association based on the number of documents in which the relation is found and also on the semantic relevance of the link, determined by the natural language processing algorithm.

We performed independent searches on WDD with 27 inflammatory diseases, 63 infectious diseases, and 9 psychiatric and neurological disorders (Table S1) in July 2018. WDD returned lists of genes related to these diseases according to the scientific literature in each year from 1990 to 2018. These associations are cumulative, that is, the genes associated with the diseases in 2018 include all the associations present in the previous year. We only kept connections between genes and diseases supported by a confidence score of at least 50% and 2 documents of evidence. Custom R code was used to process, filter, and analyze data and to plot figures. The full code of all analyses and figures in this study is available at https://github.com/csbl-usp/evolution_of_knowledge.

Evolution of knowledge

We calculated Fisher's exact test p-value of the gene overlap between each pair of diseases in each year from 1990 to 2018. The total number of genes connected in the network in each year was used as Fisher's exact test universe. For each year, a disease-disease knowledge network was developed using the $-\log_{10}$pval of the Fisher's exact test ("disease-disease similarity") as the edge weight for each disease pair. The networks were constructed using the R package *igraph* (Csardi and Nepusz, 2006) and plotted using the package *ggraph*. We detected new genes in each year by comparing the list of genes of the diseases in one year to the list of genes of the same disease in the previous year. Thus, we obtained a list of new genes that were added to the network in each year from 1991 to 2018. The total number of genes associated with each disease was also calculated for each year. Line, violin, and ridge plots were created to illustrate the results using *ggplot2* (Wickham, 2016).

Evolution of disease relationships between categories

For the top 9 diseases of each category that were connected to the most genes in 2018 ("top 9 diseases"), we detected the diseases from the other two categories with the most significant gene sharing between them ("disease pairs") and analyzed how these relationships evolved from 1990 to 2018. The disease-disease similarity scores obtained previously were also used in this analysis. We used the *MeSH.db* R package (Tsuyuzaki et al., 2015) to obtain the MeSH IDs and terms of all 99 diseases. Using the obtained MeSH terms of the diseases in each pair, we used the *easyPubMed* R package to search for PubMed papers in which both disease MeSHes were found together. We then used an adapted version of the *fetch_pubmed_data* function (see code in GitHub) of the *easyPubMed* package to retrieve the number of papers that

602 contained the searched MeSH pairs in each year from 1990 to 2018. We used the disease-
603 disease similarity score and the number of papers in 2018 to calculate a similarity-to-paper ratio
604 for each disease pair as follows:

$$similarity.paper.ratio = \frac{dis.dis.similarity}{numberofpapers}$$

605 Low similarity-to-paper ratios (<10) were considered as cases of low knowledge gap between
606 the gene sharing and the general scientific interest in the disease pairs. Pairs in this category
607 included those in which the diseases did not share a significant amount of genes or pairs of
608 similar diseases for which there is also a proportional number of papers that cite the two
609 diseases together. Ratios between 10 and 40 were considered as cases of intermediate
610 knowledge gap, that is, the diseases in the pair are similar in the genes they share, but the
611 number of papers on the two diseases together is not proportionally high. High similarity-to-
612 paper ratios (>40) were interpreted as cases of a large knowledge gap. The pairs that fell in this
613 category include diseases that share a significant proportion of their genes but that have almost
614 never been studied together, evidenced by the very low number of papers including the two
615 MeSH terms.

616

617 **Evolution of biological pathways**

618 We used the *enricher* function of the R package *clusterProfiler* (Yu et al., 2012) to
619 perform an ORA against Reactome pathways of the genes associated with the top 9 diseases of
620 each category in each year. We selected the significant Reactome pathways (p.adjust < 0.01) of
621 the top 9 diseases in 2018 and calculated the significance of the gene overlap between these
622 pathways with Fisher's exact test. We considered only the genes of each significant pathway
623 that were also present in the 2018 gene-disease network. By doing this, we limited pathways to

cluster according to the genes shared from our data set, not all the genes in the pathways. We then built a pathway network connecting the significant Reactome terms using the $-\log_{10}$pvalue of the Fisher's exact tests as edge weights, similar to what was done for the disease-disease network in Fig. 1A. We detected clusters of pathways in this network using the *cluster_louvain* function (Blondel et al., 2008) of the *igraph* R package (Csardi and Nepusz, 2006). Edge weights were considered for the cluster detection. We calculated the weighted degree of each pathway in the network using the *strength* function of the *igraph* package (Csardi and Nepusz, 2006). We manually annotated the detected clusters for their major biological function using the pathways with the highest weighted degree in each cluster as reference. The significance values ($-\log_{10}$pval) of ORA for the pathways in each cluster were used to make box and ridge plots to illustrate the results for each disease in 2018 and how these results changed from 1990 to 2018.

Evolution of drug target hub genes

Using the 2018 gene-disease network, we detected the genes common to all three categories of diseases ("hub genes"). We used the R package *UpsetR* to visualize the number of genes shared and exclusive to the disease categories. We downloaded the drug-gene and the drug-disease interaction databases from the CTD (http://ctdbase.org/; Davis et al., 2021). We used the MeSH terms of the 99 diseases to filter the drug-disease database and kept only interactions between drugs and diseases that were listed as "therapeutic" by CTD. These are cases of a "chemical that has a known or potential therapeutic role in a disease (e.g., chemical X is used to treat leukemia)", according to the CTD glossary (Davis et al., 2021). We filtered the drug-gene database and kept only the interactions between the therapeutic drugs and the hub

genes of our analysis. This final drug-gene list was used to detect the top 20 drugs that target the most hub genes and the top 20 hub genes most targeted by the therapeutic drugs. We visualized these drug-gene interactions in a network built with the R packages *igraph* and plotted with *ggplot2* and *ggraph*. We used the yearly gene-disease networks to detect when the top 20 drug target hub genes were first connected to diseases in each category to build a timeline.

Competing interests

We declare that the authors have no conflicts of interest.

Data availability

The data and code used to produce the analyses and figures in this study are available at https://github.com/csbl-usp/evolution_of_knowledge.

Author Contribution

Conceptualization, Investigation, Data Curation and Writing: TLD, RJSD, PPA, VS, GRF and HIN. Software Programming, Formal analysis: TLD, VS, TLA. Repository was developed by TLD and TLA. Resources, Writing Review & Editing: TLD, RJSD, PPA, VS, GRF and HIN; Supervision and Funding acquisition: GRF and HIN.

Funding

This work was supported by Brazilian National Council for Scientific and Technological Development (grant numbers 313662/2017-7); the São Paulo Research Foundation (grant

numbers 2018/14933-2).

672 **References**

673 Bai T, Gong L, Wang Ye, Wang Yan, Kulikowski CA, Huang L. 2016. A method for exploring
674 implicit concept relatedness in biomedical knowledge network. *BMC Bioinformatics* **17**
675 **Suppl 9**:265. doi:10.1186/s12859-016-1131-5
676 Balak DM, Hajdarbegovic E. 2017. Drug-induced psoriasis: clinical perspectives. *Psoriasis*
677 *(Auckl)* **7**:87–94. doi:10.2147/PTT.S126727
678 Barabási A-L, Gulbahce N, Loscalzo J. 2011. Network medicine: a network-based approach to
679 human disease. *Nat Rev Genet* **12**:56–68. doi:10.1038/nrg2918
680 Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. 2012. Hydroxychloroquine: from malaria to
681 autoimmunity. *Clin Rev Allergy Immunol* **42**:145–153. doi:10.1007/s12016-010-8243-x
682 Blondel VD, Guillaume J-L, Lambiotte R, Lefebvre E. 2008. Fast unfolding of communities in
683 large networks. *J Stat Mech* **2008**:P10008. doi:10.1088/1742-5468/2008/10/P10008
684 Brew BJ, Garber JY. 2018. Neurologic sequelae of primary HIV infection. *Handb Clin Neurol*
685 **152**:65–74. doi:10.1016/B978-0-444-63849-6.00006-2
686 Brooks PJ, Tagle DA, Groft S. 2014. Expanding rare disease drug trials based on shared
687 molecular etiology. *Nat Biotechnol* **32**:515–518. doi:10.1038/nbt.2924
688 Carson MB, Liu C, Lu Y, Jia C, Lu H. 2017. A disease similarity matrix based on the uniqueness
689 of shared genes. *BMC Med Genomics* **10**:26. doi:10.1186/s12920-017-0265-2
690 Chateauvieux S, Morceau F, Dicato M, Diederich M. 2010. Molecular and therapeutic potential
691 and toxicity of valproic acid. *J Biomed Biotechnol* **2010**. doi:10.1155/2010/479364
692 Chaudhry IB, Husain MO, Khoso AB, Husain MI, Buch MH, Kiran T, Fu B, Bassett P, Qurashi I,
693 Ur Rahman R, Baig S, Kazmi A, Corsi-Zuelli F, Haddad PM, Deakin B, Husain N. 2020. A
694 randomised clinical trial of methotrexate points to possible efficacy and adaptive immune
695 dysfunction in psychosis. *Transl Psychiatry* **10**:415. doi:10.1038/s41398-020-01095-8
696 Chen H, Liu S, Ji L, Wu T, Ji Y, Zhou Y, Zheng M, Zhang M, Xu W, Huang G. 2016. Folic acid
697 supplementation mitigates alzheimer's disease by reducing inflammation: A randomized
698 controlled trial. *Mediators Inflamm* **2016**:5912146. doi:10.1155/2016/5912146
699 Chen S, Ye J, Chen X, Shi J, Wu W, Lin Wenping, Lin Weibin, Li Y, Fu H, Li S. 2018. Valproic
700 acid attenuates traumatic spinal cord injury-induced inflammation via STAT1 and NF-κB
701 pathway dependent of HDAC3. *J Neuroinflammation* **15**:150. doi:10.1186/s12974-018-
702 1193-6
703 Chen Y, Elenee Argentinis JD, Weber G. 2016. IBM watson: how cognitive computing can be
704 applied to big data challenges in life sciences research. *Clin Ther* **38**:688–701.
705 doi:10.1016/j.clinthera.2015.12.001
706 Chen Y-L, Jing J, Mo Y-Q, Ma J-D, Yang L-J, Chen L-F, Zhang X, Yan T, Zheng D-H, Pessler F,
707 Dai L. 2018. Presence of hepatitis B virus in synovium and its clinical significance in
708 rheumatoid arthritis. *Arthritis Res Ther* **20**:130. doi:10.1186/s13075-018-1623-y
709 Clayton KA, Van Enoo AA, Ikezu T. 2017. Alzheimer's disease: the role of microglia in brain
710 homeostasis and proteopathy. *Front Neurosci* **11**:680. doi:10.3389/fnins.2017.00680
711 Costalonga EC, Silva FMO, Noronha IL. 2016. Valproic Acid Prevents Renal Dysfunction and

712 Inflammation in the Ischemia-Reperfusion Injury Model. *Biomed Res Int* **2016**:5985903.
713 doi:10.1155/2016/5985903
714 Csardi G, Nepusz T. 2006. The igraph software package for complex network research.
715 *InterJournal* **Complex Systems**:1695.
716 Dalakas MC. 2020. Guillain-Barré syndrome: The first documented COVID-19-triggered
717 autoimmune neurologic disease: More to come with myositis in the offing. *Neurol*
718 *Neuroimmunol Neuroinflamm* **7**. doi:10.1212/NXI.0000000000000781
719 Davis AP, Grondin CJ, Johnson RJ, Sciaky D, Wiegers J, Wiegers TC, Mattingly CJ. 2021.
720 Comparative Toxicogenomics Database (CTD): update 2021. *Nucleic Acids Res*
721 **49**:D1138–D1143. doi:10.1093/nar/gkaa891
722 de Baumont A, Maschietto M, Lima L, Carraro DM, Olivieri EH, Fiorini A, Barreta LAN, Palha
723 JA, Belmonte-de-Abreu P, Moreira Filho CA, Brentani H. 2015. Innate immune response is
724 differentially dysregulated between bipolar disease and schizophrenia. *Schizophr Res*
725 **161**:215–221. doi:10.1016/j.schres.2014.10.055
726 De Felice C, Leoncini S, Signorini C, Cortelazzo A, Rovero P, Durand T, Ciccoli L, Papini AM,
727 Hayek J. 2016. Rett syndrome: An autoimmune disease? *Autoimmun Rev* **15**:411–416.
728 doi:10.1016/j.autrev.2016.01.011
729 Dong D, Zielke HR, Yeh D, Yang P. 2018. Cellular stress and apoptosis contribute to the
730 pathogenesis of autism spectrum disorder. *Autism Res* **11**:1076–1090.
731 doi:10.1002/aur.1966
732 Dong Y, Lagarde J, Xicota L, Corne H, Chantran Y, Chaigneau T, Crestani B, Bottlaender M,
733 Potier M-C, Aucouturier P, Dorothée G, Sarazin M, Elbim C. 2018. Neutrophil
734 hyperactivation correlates with Alzheimer's disease progression. *Ann Neurol* **83**:387–405.
735 doi:10.1002/ana.25159
736 Dugger BN, Dickson DW. 2017. Pathology of neurodegenerative diseases. *Cold Spring Harb*
737 *Perspect Biol* **9**. doi:10.1101/cshperspect.a028035
738 Eimer WA, Vijaya Kumar DK, Navalpur Shanmugam NK, Rodriguez AS, Mitchell T, Washicosky
739 KJ, György B, Breakefield XO, Tanzi RE, Moir RD. 2018. Alzheimer's Disease-Associated
740 β-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection. *Neuron*
741 **100**:1527–1532. doi:10.1016/j.neuron.2018.11.043
742 Fortunato S, Bergstrom CT, Börner K, Evans JA, Helbing D, Milojević S, Petersen AM, Radicchi
743 F, Sinatra R, Uzzi B, Vespignani A, Waltman L, Wang D, Barabási A-L. 2018. Science of
744 science. *Science* **359**. doi:10.1126/science.aao0185
745 Galvez-Sánchez CM, Montoro CI, Duschek S, Reyes Del Paso GA. 2020. Depression and trait-
746 anxiety mediate the influence of clinical pain on health-related quality of life in fibromyalgia.
747 *J Affect Disord* **265**:486–495. doi:10.1016/j.jad.2020.01.129
748 Gandal MJ, Zhang P, Hadjimichael E, Walker RL, Chen C, Liu S, Won H, van Bakel H,
749 Varghese M, Wang Y, Shieh AW, Haney J, Parhami S, Belmont J, Kim M, Moran Losada P,
750 Khan Z, Mleczko J, Xia Y, Dai R, Geschwind DH. 2018. Transcriptome-wide isoform-level
751 dysregulation in ASD, schizophrenia, and bipolar disorder. *Science* **362**.

doi:10.1126/science.aat8127

Getts DR, Chastain EML, Terry RL, Miller SD. 2013. Virus infection, antiviral immunity, and autoimmunity. *Immunol Rev* **255**:197–209. doi:10.1111/imr.12091

Gibney SM, Drexhage HA. 2013. Evidence for a dysregulated immune system in the etiology of psychiatric disorders. *J Neuroimmune Pharmacol* **8**:900–920. doi:10.1007/s11481-013-9462-8

Goodwin DG, Strobl J, Mitchell SM, Zajac AM, Lindsay DS. 2008. Evaluation of the mood-stabilizing agent valproic acid as a preventative for toxoplasmosis in mice and activity against tissue cysts in mice. *J Parasitol* **94**:555–557. doi:10.1645/GE-1331.1

Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T. 2001. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. *EMBO J* **20**:6969–6978. doi:10.1093/emboj/20.24.6969

Gravani A, Gaitanis G, Zioga A, Bassukas ID. 2014. Synthetic antimalarial drugs and the triggering of psoriasis - do we need disease-specific guidelines for the management of patients with psoriasis at risk of malaria? *Int J Dermatol* **53**:327–330. doi:10.1111/ijd.12231

Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC. 1996. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. *N Engl J Med* **335**:1081–1090. doi:10.1056/NEJM199610103351501

Harris SA, Harris EA. 2015. Herpes simplex virus type 1 and other pathogens are key causative factors in sporadic alzheimer's disease. *J Alzheimers Dis* **48**:319–353. doi:10.3233/JAD-142853

Hull EE, Montgomery MR, Leyva KJ. 2016. HDAC inhibitors as epigenetic regulators of the immune system: impacts on cancer therapy and inflammatory diseases. *Biomed Res Int* **2016**:8797206. doi:10.1155/2016/8797206

Hwang ES. 2010. Transcriptional regulation of T helper 17 cell differentiation. *Yonsei Med J* **51**:484–491. doi:10.3349/ymj.2010.51.4.484

Kohler O, Krogh J, Mors O, Benros ME. 2016. Inflammation in Depression and the Potential for Anti-Inflammatory Treatment. *Curr Neuropharmacol* **14**:732–742. doi:10.2174/1570159x14666151208113700

Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, et al. 2001. Initial sequencing and analysis of the human genome. *Nature* **409**:860–921. doi:10.1038/35057062

Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. *J Exp Med* **201**:233–240. doi:10.1084/jem.20041257

Lees CW, Barrett JC, Parkes M, Satsangi J. 2011. New IBD genetics: common pathways with

792 other diseases. *Gut* **60**:1739–1753. doi:10.1136/gut.2009.199679
793 Leonard BE. 2018. Inflammation and depression: a causal or coincidental link to the
794 pathophysiology? *Acta Neuropsychiatr* **30**:1–16. doi:10.1017/neu.2016.69
795 Li H-M, Huang Y-K, Su Y-C, Kao C-H. 2018. Increased risk of autoimmune diseases in dengue
796 patients: A population-based cohort study. *J Infect* **77**:212–219.
797 doi:10.1016/j.jinf.2018.03.014
798 Littmann M, Selig K, Cohen-Lavi L, Frank Y, Hönigschmid P, Kataka E, Mösch A, Qian K, Ron
799 A, Schmid S, Sorbie A, Szlak L, Dagan-Wiener A, Ben-Tal N, Niv MY, Razansky D,
800 Schuller BW, Ankerst D, Hertz T, Rost B. 2020. Validity of machine learning in biology and
801 medicine increased through collaborations across fields of expertise. *Nat Mach Intell*.
802 doi:10.1038/s42256-019-0139-8
803 Liyanage VRB, Rastegar M. 2014. Rett syndrome and MeCP2. *Neuromolecular Med* **16**:231–
804 264. doi:10.1007/s12017-014-8295-9
805 Lüscher Dias T, Schuch V, Beltrão-Braga PCB, Martins-de-Souza D, Brentani HP, Franco GR,
806 Nakaya HI. 2020. Drug repositioning for psychiatric and neurological disorders through a
807 network medicine approach. *Transl Psychiatry* **10**:141. doi:10.1038/s41398-020-0827-5
808 Madore C, Leyrolle Q, Lacabanne C, Benmamar-Badel A, Joffre C, Nadjar A, Layé S. 2016.
809 Neuroinflammation in autism: plausible role of maternal inflammation, dietary omega 3, and
810 microbiota. *Neural Plast* **2016**:3597209. doi:10.1155/2016/3597209
811 Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, Berka J, Braverman MS,
812 Chen Y-J, Chen Z, Dewell SB, Du L, Fierro JM, Gomes XV, Godwin BC, He W, Helgesen
813 S, Ho CH, Irzyk GP, Jando SC, Rothberg JM. 2005. Genome sequencing in
814 microfabricated high-density picolitre reactors. *Nature* **437**:376–380.
815 doi:10.1038/nature03959
816 Marks M, Marks JL. 2016. Viral arthritis. *Clin Med* **16**:129–134. doi:10.7861/clinmedicine.16-2-
817 129
818 Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA,
819 El-Gabalawy R, Katz A, Fisk JD, Bernstein CN, CIHR Team in Defining the Burden and
820 Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.
821 2017. Increased incidence of psychiatric disorders in immune-mediated inflammatory
822 disease. *J Psychosom Res* **101**:17–23. doi:10.1016/j.jpsychores.2017.07.015
823 Mirise RT, Kitridou RC. 1979. Arthritis and hepatitis. *West J Med* **130**:12–17.
824 Nalbant A, Eskier D. 2016. Genes associated with T helper 17 cell differentiation and function.
825 *Front Biosci (Elite Ed)* **8**:427–435. doi:10.2741/e777
826 Newcombe EA, Camats-Perna J, Silva ML, Valmas N, Huat TJ, Medeiros R. 2018.
827 Inflammation: the link between comorbidities, genetics, and Alzheimer's disease. *J*
828 *Neuroinflammation* **15**:276. doi:10.1186/s12974-018-1313-3
829 Nygaard G, Firestein GS. 2020. Restoring synovial homeostasis in rheumatoid arthritis by
830 targeting fibroblast-like synoviocytes. *Nat Rev Rheumatol* **16**:316–333.
831 doi:10.1038/s41584-020-0413-5

Ozben T, Ozben S. 2019. Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease. *Clin Biochem* **72**:87–89. doi:10.1016/j.clinbiochem.2019.04.001

Pandurangi AK, Buckley PF. 2020. Inflammation, Antipsychotic Drugs, and Evidence for Effectiveness of Anti-inflammatory Agents in Schizophrenia. *Curr Top Behav Neurosci* **44**:227–244. doi:10.1007/7854_2019_91

Pitt B, Sutton NR, Wang Z, Goonewardena SN, Holinstat M. 2021. Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19. *Eur J Pharmacol* **898**:173988. doi:10.1016/j.ejphar.2021.173988

Postma DS, Kerkhof M, Boezen HM, Koppelman GH. 2011. Asthma and chronic obstructive pulmonary disease: common genes, common environments? *Am J Respir Crit Care Med* **183**:1588–1594. doi:10.1164/rccm.201011-1796PP

Rajkomar A, Oren E, Chen K, Dai AM, Hajaj N, Hardt M, Liu PJ, Liu X, Marcus J, Sun M, Sundberg P, Yee H, Zhang K, Zhang Y, Flores G, Duggan GE, Irvine J, Le Q, Litsch K, Mossin A, Dean J. 2018. Scalable and accurate deep learning with electronic health records. *npj Digital Med* **1**:18. doi:10.1038/s41746-018-0029-1

RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Landray MJ. 2021. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med* **384**:693–704. doi:10.1056/NEJMoa2021436

Rosenblat JD, Kakar R, Berk M, Kessing LV, Vinberg M, Baune BT, Mansur RB, Brietzke E, Goldstein BI, McIntyre RS. 2016. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. *Bipolar Disord* **18**:89–101. doi:10.1111/bdi.12373

Scuderi C, Verkhratsky A. 2020. The role of neuroglia in autism spectrum disorders. *Prog Mol Biol Transl Sci* **173**:301–330. doi:10.1016/bs.pmbts.2020.04.011

Sethi MK, Zaia J. 2017. Extracellular matrix proteomics in schizophrenia and Alzheimer's disease. *Anal Bioanal Chem* **409**:379–394. doi:10.1007/s00216-016-9900-6

Shi X, Liu Y, Zhang D, Xiao D. 2019. Valproic acid attenuates sepsis-induced myocardial dysfunction in rats by accelerating autophagy through the PTEN/AKT/mTOR pathway. *Life Sci* **232**:116613. doi:10.1016/j.lfs.2019.116613

Tomson T, Battino D, Perucca E. 2016. The remarkable story of valproic acid. *Lancet Neurol* **15**:141. doi:10.1016/S1474-4422(15)00398-1

Tshitoyan V, Dagdelen J, Weston L, Dunn A, Rong Z, Kononova O, Persson KA, Ceder G, Jain A. 2019. Unsupervised word embeddings capture latent knowledge from materials science literature. *Nature* **571**:95–98. doi:10.1038/s41586-019-1335-8

Tsuyuzaki K, Morota G, Ishii M, Nakazato T, Miyazaki S, Nikaido I. 2015. MeSH ORA framework: R/Bioconductor packages to support MeSH over-representation analysis. *BMC Bioinformatics* **16**:45. doi:10.1186/s12859-015-0453-z

Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans

CA, Holt RA, Gocayne JD, Amanatides P, Ballew RM, Huson DH, Wortman JR, Zhang Q, Kodira CD, Zheng XH, Chen L, Skupski M, et al. 2001. The sequence of the human genome. *Science* **291**:1304–1351. doi:10.1126/science.1058040

Wang Q, Yang C, Gelernter J, Zhao H. 2015. Pervasive pleiotropy between psychiatric disorders and immune disorders revealed by integrative analysis of multiple GWAS. *Hum Genet* **134**:1195–1209. doi:10.1007/s00439-015-1596-8

Wickham H. 2016. ggplot2 - Elegant Graphics for Data Analysis, 2nd ed. Cham: Springer International Publishing. doi:10.1007/978-3-319-24277-4

Yuan N, Chen Y, Xia Y, Dai J, Liu C. 2019. Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses. *Transl Psychiatry* **9**:233. doi:10.1038/s41398-019-0570-y

Yu G, Wang L-G, Han Y, He Q-Y. 2012. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS* **16**:284–287. doi:10.1089/omi.2011.0118

Zambrano-Zaragoza JF, Romo-Martínez EJ, Durán-Avelar M de J, García-Magallanes N, Vibanco-Pérez N. 2014. Th17 cells in autoimmune and infectious diseases. *Int J Inflam* **2014**:651503. doi:10.1155/2014/651503

Zitnik M, Nguyen F, Wang B, Leskovec J, Goldenberg A, Hoffman MM. 2019. Machine learning for integrating data in biology and medicine: principles, practice, and opportunities. *Inf Fusion* 50:71–91. doi:10.1016/j.inffus.2018.09.012